How to Help Your Patients Find Atzumi in Stock: A Provider's Guide

When you prescribe Atzumi (dihydroergotamine 5.2 mg nasal powder) to a patient with migraine, the clinical decision is only half the work in 2026. As a newly-launched specialty drug, Atzumi is still building out its retail pharmacy presence and formulary coverage. Your patients will need active support navigating the access process — and proactive steps from your office can dramatically shorten the time from prescription to medication in hand.

This guide gives you specific, actionable steps to help patients find Atzumi quickly.

Step 1: Submit the Prior Authorization at the Same Time as the Prescription

The single most impactful thing you can do is submit the prior authorization simultaneously with the prescription. PA processing takes 1–14 business days depending on the payer. If you send the prescription first and start the PA later, your patient waits in queue twice. Most major PBMs require PA for Atzumi — Caremark added it to their dihydroergotamine PA policy effective June 2025. Build a PA submission workflow into your prescription process for Atzumi from day one.

What to Include in the PA Documentation

A strong PA submission for Atzumi should include:

Confirmed migraine diagnosis (ICD-10 code and clinical documentation)

List of triptans and other acute migraine treatments trialed, with dates, doses, and reasons for failure or contraindication

Clinical rationale for DHE specifically: e.g., high recurrence migraine, late-presenting attacks, status migrainosus, triptan contraindication (cardiovascular history)

Cardiovascular evaluation documentation per Atzumi PI (or documentation that patient is low CV risk)

Step 2: Send the Prescription to Multiple Pharmacies Simultaneously

Rather than sending Atzumi to a single pharmacy and waiting to hear back about stock, consider sending it to both a specialty pharmacy (that your insurer designates) and a large retail chain simultaneously. Most states allow a prescription to be sent to one pharmacy at a time, but you can cancel and reroute if needed. Alternatively, instruct your patient to use medfinder to identify which local pharmacy actually has stock before you route the prescription there.

Step 3: Direct Patients to medfinder for Pharmacy Search

One of the most practical tools you can give patients is a referral to medfinder.com. medfinder is a paid service that calls pharmacies near the patient to identify which ones can fill their Atzumi prescription. This dramatically reduces the frustrating phone-tag process where patients call pharmacy after pharmacy only to be told the drug isn't in stock.

Giving patients this resource at the point of prescribing — ideally a printed handout or an after-visit summary item — sets realistic expectations and gives them a concrete next step.

Step 4: Know Satsuma's Patient Support Program

Satsuma Pharmaceuticals (satsumarx.com, 1-888-273-2480) offers patient support services that can assist with coverage determination, pharmacy navigation, and savings programs. When you or your staff refer a patient to Satsuma's patient support, they can help identify appropriate pharmacies and explore manufacturer savings options that may reduce the patient's out-of-pocket cost.

Step 5: Have a Bridge Strategy Ready

Anticipate that some patients will experience delays. A bridge strategy prevents migraine attacks from going untreated while Atzumi access is being established. Options include:

Generic DHE nasal spray: Same active ingredient, widely available, lower cost. Appropriate bridge while Atzumi PA is pending.

Trudhesa: Established formulary coverage; same drug class; precision nasal delivery.

CGRP antagonist (gepant): Appropriate if patient has cardiovascular risk factors or cannot use DHE for clinical reasons.

Office samples: Ask your Satsuma pharmaceutical representative for starter samples that can be dispensed to patients while their prescription is being processed.

Handling PA Denials

If an initial PA is denied, appeal with additional clinical documentation and request a peer-to-peer review if available. Key talking points for peer-to-peer: the clinical evidence for DHE's superior efficacy in triptan non-responders, the lack of cardiovascular contraindications in this patient, Atzumi's demonstrated pharmacokinetic advantages over older DHE formulations, and the FDA's recent approval based on Phase 3 safety data. Many initial PA denials are overturned at the peer-to-peer stage.

Summary: Atzumi Provider Access Checklist

Submit PA simultaneously with prescription

Include step therapy documentation in PA (triptans tried, contraindications)

Perform or document cardiovascular evaluation

Direct patient to medfinder.com to check local pharmacy availability

Provide Satsuma's patient support number (1-888-273-2480) at point of prescribing

Have a bridge prescription ready (generic DHE spray or triptan)

Appeal any PA denials with peer-to-peer review